Long-term danazol therapy in autoimmune thrombocytopenia: unmaintained remission and age-dependent response in women

Yeon S. Ahn, Y S Ahn, Rafael Rocha, R Rocha, R Mylvaganam, Ravindra Mylvaganam, R. Garcia, Rolando Garcia, R Duncan, Robert Duncan, William J. Harrington, W J Harrington
Annals of internal medicine · 1989 · vol. 111(9) , pp. 723–729 · doi:10.7326/0003-4819-111-9-723 · PMID:2802430 · W2079640659
Non-randomised trial OA: closed CC0 ⤵ 14 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-08 ⓘ

Long-term danazol therapy for autoimmune thrombocytopenia achieved a 61.4% response rate with lasting remissions after prolonged administration, influenced by patient age, sex, and spleen status.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

STUDY OBJECTIVE: To assess the long-term benefit and side effects of danazol therapy, and to delineate factors influencing the responses in patients with autoimmune thrombocytopenia. DESIGN: Before and after trial. SETTING: Referral-based hematology clinics and the University of Miami teaching hospitals. PATIENTS: Data were collected on 96 patients (60 women and 36 men, 45 of whom had had splenectomies) receiving danazol therapy for autoimmune thrombocytopenia and analyzed. INTERVENTION: Danazol was added to the previous therapy or begun as an initial therapy. Glucocorticoids were tapered gradually. MEASUREMENTS AND MAIN RESULTS: The overall response rate to danazol was 61.4%. Among responders, the platelet counts (mean +/- SD) before and after danazol treatment were 36 +/- 24 x 10(9)/L and 145 +/- 77 x 10(9)/L, respectively, and the time to response was 2.7 +/- 3 months. Sex, age, and the status of the spleen (absent or present) influenced the responses to danazol. In women, but not in men, response rates improved with advancing age, especially in the nonsplenectomized women. This may be because estrogen levels are high in younger women and low in older women and men. Danazol, when given longer than a year, induced remissions lasting for years even after its discontinuation, but early relapses were frequent when danazol was administered for less than 6 months. Platelet-associated IgG returned to normal range during unmaintained remission. CONCLUSION: Danazol is best suited for long-term medical management of autoimmune thrombocytopenia. It is well tolerated, and lasting, unmaintained remissions often occur after prolonged danazol administration. Age, sex, and the status of the spleen influence the responses. When danazol therapy is used, glucocorticoids can be substantially reduced in dosage or withdrawn. Danazol is a good alternative to splenectomy in elderly persons, especially in women.

My notes (saved in your browser only)

MeSH descriptors

Autoimmune Diseases Danazol Pregnadienes Purpura, Thrombocytopenic Adolescent Adult Aged Aged, 80 and over Age Factors Autoimmune Diseases Blood Platelets Blood Platelets Danazol Danazol Drug Therapy, Combination Female Follow-Up Studies Glucocorticoids Glucocorticoids Humans

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (35)

Cited by (14)

Source provenance

openalex
last seen: 2026-05-11T06:16:32.963054+00:00
pubmed
last seen: 2026-10-08T21:19:08.299311+00:00
unpaywall
last seen: 2026-10-14T06:23:58.021457+00:00
License: CC0 · commercial use OK